Boston, Massachusetts 2021-06-09 09:19:12 –
Rise and Shine Everyone, busy days continue. Yes, yes, the middle of the week is already here. In other words, there is a lot to do. Without a doubt, you can empathize at some level. Please participate. Get a glass of inspiration (no prescription required) and face online phone calls and deadlines. Meanwhile, we will introduce the latest useful items. Keep your journey running smoothly and stay in touch as usual. …
Biogen and the Food and Drug Administration are at odds over the timing of confirmation trials of the company’s Alzheimer’s disease treatment. STAT I will report. Hours after approval, Biogen CEO Michel Vonazzos said it could take up to nine years to meet the post-approval requirements for conducting a brand new clinical trial. His remarks were not well accepted within the institution as they suggested that Biogen did not feel the urgency to complete the study in a timely manner.
Biogen and FDA at odds over key Alzheimer’s drug trial Source link Biogen and FDA at odds over key Alzheimer’s drug trial